摘要
目的:探讨阿德福韦酯在乙肝肝硬化患者中的临床效果及对患者肝硬化指标(肝脏纤维化指标)的影响。方法:选取2016年10月-2017年3月本院收治的乙肝肝硬化患者120例。根据治疗方案不同分为对照组和观察组,各60例。对照组采用拉米夫定治疗,观察组在对照组基础上联合阿德福韦酯治疗,两组均治疗3个月。比较两组治疗前后的肝功能指标(ALT、AST、ALB)、炎症因子水平(TGF-β1、IL-8)、肝脏纤维化指标(HA、LN、Ⅳ-C和PCⅢ),以及治疗后的HBV-DNA转阴率。结果:治疗后3个月,观察组ALT、AST、TGF-β1、IL-8水平均低于对照组,ALB水平高于对照组,比较差异均有统计学意义(P<0.05);治疗后3个月,观察组HA、LN、Ⅳ-C和PCⅢ水平均低于对照组,比较差异均有统计学意义(P<0.05);治疗后1、2、3个月,观察组HBV-DNA转阴率均高于对照组(P<0.05)。结论:在拉米夫定基础上联合阿德福韦酯治疗肝硬化有助于改善患者肝功能水平及肝硬化指标,降低炎症因子水平,提高HBV-DNA转阴率,值得推广应用。
Objective:To investigate the clinical effect of Adefovir Dipivoxil in patients with hepatitis B cirrhosis and its influence on liver cirrhosis index(liver fibrosis index).Method:A total of 120 patients with hepatitis B cirrhosis who were admitted to hospital from October 2016 to March 2017 were selected.According to different treatment regimens,they were divided into control group and observation group,60 cases in each group.The control group was treated with Lamivudine and observation group was treated with Adefovir Dipivoxil on the basis of control group,they were treated for 3 months.The liver function indexes(ALT,AST,ALB),inflammatory factors(TGF-β1,IL-8),liver fibrosis indexes(HA,LN,Ⅳ-C and PCⅢ)before and after treatment,and HBV-DNA negative rate after treatment between two groups were compared.Result:After 3 months of treatment,the levels of ALT,AST,TGF-β1 and IL-8 in observation group were lower than those of control group,and the levels of ALB was higher than those of control group,the differences were statistically significant(P<0.05).After 3 months treatment,the levels of HA,LN,Ⅳ-C and PCⅢin observation group were lower than those of control group(P<0.05).At 1,2 and 3 months after treatment,the negative rate of HBV-DNA in observation group were higher than those of control group(P<0.05).Conclusion:On the basis of Lamivudine combined with Adefovir Dipivoxil in treatment of cirrhosis is helpful to improve the level of liver function and liver cirrhosis indicators,reduce the level of inflammatory factors,improve the HBV-DNA negative rate,it is worthy of popularizing and applying.
作者
孙涛
于淼鑫
SUN Tao;YU Miaoxin(Jiamusi Infectious Disease Hospital,Jiamusi 154007,China)
出处
《中国医学创新》
CAS
2018年第28期45-48,共4页
Medical Innovation of China
